fda warning letter hims compounded semaglutide 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company & Hers to yank its new (Wegovy) weight-loss pill from the FDA Sends 30 Warning Letters

You may qualify with a BMI of 35 or higher

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks

NICE recommended it (TA875) for use within specialist weight management services in adults meeting specific BMI and comorbidity criteria

It serves several functions, including: Triggering your pancreas to release insulin, which lowers blood sugar Suppressing glucagon, a hormone that raises blood sugar Slowing down your digestion Increasing your feelings of fullness after eating GLP-1 medications mimic this natural hormone by binding to GLP-1 receptors in the body, and they are intended to be used alongside a healthy diet and exercise

Think of this as laying the groundwork for more significant results down the road